7 completed, 4 terminated, 3 not yet recruiting, 2 active not recruiting. 19 Phase 1, 8 Phase 2.
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS [11C]CPPC PET ligand - ALS | Phase 1 / Phase 2 | Not yet recruiting | Johns Hopkins University | 20 | 2026-11-01 | 2026-08-25 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients PLL001 or placebo daily subcutaneous injections - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Not yet recruiting | PLL TX AUSTRALIA PTY LTD | 153 | 2026-04-08 | 2026-03-19 |
| Kamlanoflast In Amyotrophic Lateral Sclerosis Kamlanoflast - ALS (Amyotrophic Lateral Sclerosis), ALS | Phase 1 / Phase 2 | Not yet recruiting | Inflammasome Therapeutics | 40 | 2026-02-01 | 2026-02-09 |
| Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) Next Generation Dome Helmet Focused Ultrasound, Intravenous immunoglobulin (IVIG), 10% solution for infusion, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 6 | 2025-04-15 | 2026-07-14 |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis AMX0114, Placebo - ALS | Phase 1 | Recruiting | Amylyx Pharmaceuticals Inc. | 48 | 2025-04-07 | 2026-04-14 |
| A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients TCD601 - ALS | Phase 1 | Terminated | ITB-Med LLC | 7 | 2024-04-16 | 2026-07-17 |
| Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis MaaT033 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | MaaT Pharma | 15 | 2023-06-08 | 2025-06-15 |
| Adenosine 2A Receptor Antagonism and AIH in ALS Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug - ALS | Phase 1 / Phase 2 | Active not recruiting | University of Florida | 40 | 2022-06-21 | 2026-03-27 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis Fosigotifator, Placebo - ALS, Amyotrophic Lateral Sclerosis | Phase 1 | Terminated | AbbVie | 31 | 2021-09-22 | 2025-08-01 |
| PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease 11C-MC1, 11C-PS13, 18f-florbetaben - Parkinson's Disease, Dementia | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 184 | 2021-08-17 | 2026-11-02 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS AMX0035 - ALS | Phase 1 / Phase 2 | Unknown | Amylyx Pharmaceuticals Inc. | 14 | 2021-08-05 | 2023-07-24 |
| Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) WVE-004, Placebo - ALS, FTD | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 35 | 2021-06-28 | 2023-10-23 |
| Multimodal Imaging Outcome Measures for ALS (Image ALS) [11C]-PBR28 - ALS | Phase 1 | Terminated | University of Pennsylvania | 2 | 2021-02-25 | 2022-04-12 |
| Trial of Oxaloacetate in ALS Oxaloacetic Acid - ALS | Phase 1 | Completed | Omar Jawdat | 18 | 2020-03-17 | 2024-06-06 |
| A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) Triheptanoin - ALS | Phase 1 / Phase 2 | Completed | Richard Bedlack, M.D., Ph.D. | 15 | 2018-06-21 | 2019-12-24 |
| Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS BHV-0223 - Amyotrophic Lateral Sclerosis, ALS | Phase 1 | Completed | Biohaven Pharmaceuticals, Inc. | 22 | 2018-02-02 | 2022-10-06 |
| A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) RNS60 - ALS | Phase 1 | Completed | Sabrina Paganoni, M.D. | 24 | 2015-10-01 | 2021-05-28 |
| Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis HYNR-CS inj, Control group - Amyotrophic Lateral Sclerosis, ALS | Phase 1 / Phase 2 | Completed | Corestemchemon, Inc. | 72 | 2011-02-01 | 2022-03-17 |
| Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis Tongue Piercing, Usability assessment - Quadriplegia, Spinal Cord Injury | Phase 1 | Completed | Georgia Institute of Technology | 61 | 2010-05-01 | 2013-09-18 |
Amyotrophic Lateral Sclerosis (10) · Motor Neuron Disease (5) · Neurodegenerative Diseases (2) · Alzheimer Disease (1) · Cognitive Dysfunction (1) · Dementia (1) · Hypoxia (1) · Inflammation (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Paralysis (1) · Parkinson Disease (1) · Quadriplegia (1) · Respiratory Aspiration (1) · Spinal Cord Injuries (1)
Central Nervous System Diseases (12) · Nervous System Diseases (11) · Spinal Cord Diseases (11) · Metabolic Diseases (10) · Nutritional and Metabolic Diseases (10) · Proteostasis Deficiencies (10) · TDP-43 Proteinopathies (10) · Neurodegenerative Diseases (9) · Neuromuscular Diseases (9) · Motor Neuron Disease (5) · Pathological Conditions, Signs and Symptoms (3) · Pathologic Processes (2) · Signs and Symptoms (2) · Basal Ganglia Diseases (1) · Brain Diseases (1)
(11C)-MC1 (1) · (methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine (1) · 11C-PS13 (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Acetates (1) · Body Piercing (1) · Butyrates (1) · Control Groups (1) · Immunoglobulins, Intravenous (1) · Insemination, Artificial, Homologous (1) · Lactic Acid (1) · Oxaloacetic Acid (1) · Oxygen (1) · Propionates (1) · RNS60 (1)
Amylyx Pharmaceuticals Inc. (2) · AbbVie (1) · Biohaven Pharmaceuticals, Inc. (1) · Corestemchemon, Inc. (1) · Georgia Institute of Technology (1) · ITB-Med LLC (1) · Inflammasome Therapeutics (1) · Johns Hopkins University (1) · MaaT Pharma (1) · National Institute of Mental Health (NIMH) (1) · Omar Jawdat (1) · PLL TX AUSTRALIA PTY LTD (1) · Richard Bedlack, M.D., Ph.D. (1) · Sabrina Paganoni, M.D. (1) · Sunnybrook Health Sciences Centre (1)
United States (11) · Canada (4) · Sweden (2) · Australia (1) · Belgium (1) · France (1) · Ireland (1) · Netherlands (1) · New Zealand (1) · South Korea (1) · United Kingdom (1)
Barbara Smith (1) · Corey McMillan, PhD (1) · Fredrik Julin (1) · Gaelle Bruneteau, MD, PhD (1) · Maysam Ghovanloo, Ph.D. (1) · Nazem Atassi, MD (1) · Nicholas Maragakis, MD (1) · Omar Jawdat, MD (1) · Richard S Bedlack, MD PhD (1) · Robert B Innis, M.D. (1) · Sabrina Paganoni, MD (1) · Seung Hyun Kim, M.D., Ph.D. (1) · Tina Soulis (1)
PMID 21652288, PMID 22531737, PMID 22692932, PMID 24284925, PMID 25934946, PMID 30048006, PMID 39542698, PMID 41202295, PMID 42083927
1RC1EB010915-01 (1)